Latest Safety News

BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

SenSen Networks has reported a strong financial turnaround for the year ended June 2025, posting a 26.5% increase in revenue alongside a return to profitability after previous losses.

Spacetalk Limited reported a 12.2% revenue increase to $19.6 million in FY25, driven by recurring mobile subscriptions and device sales, while reducing its net loss by 27.1%. The company secured $3 million in capital post-year-end to support growth amid ongoing going concern uncertainties.

Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Regal Asian Investments has commenced on-market share purchases to satisfy its Dividend Reinvestment Plan, pricing shares at or below its recent net tangible asset value of $2.54. This move signals a strategic approach to capital management amid evolving portfolio stewardship.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.